ArticleRheumatology advances in practice2025
Achievement of lupus low disease activity state (LLDAS) in a New Zealand cohort: a prospective study of ethnic differences in outcomes.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To examine ethnic differences in LLDAS attainment and lupus nephritis (LN) in SLE patients from the Auckland, New Zealand (NZ) cohort of the Asia Pacific Lupus Collaboration (APLC) treat-to-target (T2T) Lupus Low Disease Activity State (LLDAS) study. Secondary outcomes were to explore ethnic differences in medication use, SLE damage and patient-reported health outcomes. Methods: All patients fulfilled either the 1997 American College of Rheumatology classification criteria for SLE or Systemic Lupus International Collaborating Clinics 2012 classification criteria. At each study visit, patients were assessed for LLDAS attainment, flares and medication use and assessed annually for SLE damage and patient-reported health outcomes. Results: A total of 141 patients from three Auckland tertiary hospitals were analysed during 2018-2020. Seventy-five percent ( Conclusion: This is the first NZ study to provide prospective data on SLE disease outcomes. The majority of patients were able to achieve LLDAS. There were ethnic differences in proliferative LN with overrepresentation in non-NZ European ethnic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.